Literature DB >> 15670543

In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction.

Lin Y Chen1, Ryan J Lennon, J Aaron Grantham, Peter B Berger, Verghese Mathew, Mandeep Singh, David R Holmes, Charanjit S Rihal.   

Abstract

Multivessel percutaneous coronary intervention (PCI) early after acute myocardial infarction (AMI) is discouraged because of the potential for increased complications. However, with recent advances in PCI, the safety and long-term outcomes of multivessel PCI are unknown. We evaluated the outcomes of multivessel PCI early after AMI (ST-elevation and non-ST-elevation AMI). We identified all patients who had multivessel disease and underwent PCI within 7 days after an AMI from 1997 to 2002. Clinical outcomes were compared between patients who underwent multivessel PCI (n = 239) and patients who underwent treatment of the infarct-related artery alone (n = 1,145). The primary end point was cumulative survival at 6, 12, and 36 months. Secondary end points included a composite of mortality, recurrent infarction, coronary artery bypass graft, or target vessel revascularization at the same time points. There were 138 deaths and 351 occurrences of the composite end point during follow-up. The multivessel PCI group had a significantly higher prevalence of adverse prognostic indicators. Despite this, observed event rates were similar between the multivessel PCI and 1-vessel PCI groups. The Kaplan-Meier estimated 1-year survival was 0.91 (95% confidence interval [CI] 0.87 to 0.95) for the multivessel PCI group and 0.93 (95% CI 0.92 to 0.95) for the 1-vessel PCI group (p = 0.43). Similarly, 1-year survival free of recurrent infarction and target vessel revascularization rates were similar between the 2 groups: multivessel PCI 0.78 (95% CI 0.73 to 0.84) and 1-vessel PCI 0.78 (95% CI 0.75 to 0.81). Multivessel PCI in patients with multivessel coronary artery disease after AMI compared with 1-vessel PCI was not associated with an excess risk of death or of combined death, myocardial infarction, coronary artery bypass graft, or target vessel revascularization.

Entities:  

Mesh:

Year:  2005        PMID: 15670543     DOI: 10.1016/j.amjcard.2004.09.032

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  Ubiquitin-free routes into the proteasome.

Authors:  M A Hoyt; P Coffino
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

Review 2.  Multivessel versus culprit-only revascularization: one time versus staged procedures for the ACS population.

Authors:  Pablo Codner; Ran Kornowski
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

3.  [Procedural aspects in primary PCI: arterial access, stent selection, thrombectomy and treatment of non-culprit lesions].

Authors:  N F Boeder; C W Hamm; H M Nef
Journal:  Herz       Date:  2014-09       Impact factor: 1.443

Review 4.  Complete versus culprit-only revascularisation in ST elevation myocardial infarction with multi-vessel disease.

Authors:  Claudio A Bravo; Sameer A Hirji; Deepak L Bhatt; Rachna Kataria; David P Faxon; E Magnus Ohman; Kevin L Anderson; Akil I Sidi; Michael H Sketch; Stuart W Zarich; Asishana A Osho; Christian Gluud; Henning Kelbæk; Thomas Engstrøm; Dan Eik Høfsten; James M Brennan
Journal:  Cochrane Database Syst Rev       Date:  2017-05-03

5.  Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.

Authors:  René J van der Schaaf; Bimmer E Claessen; Loes P Hoebers; Niels J Verouden; Jacques J Koolen; Maarten J Suttorp; Emanuele Barbato; Matthijs Bax; Bradley H Strauss; Göran K Olivecrona; Vegard Tuseth; Dietmar Glogar; Truls Råmunddal; Jan G Tijssen; Jan J Piek; José P S Henriques
Journal:  Trials       Date:  2010-09-21       Impact factor: 2.279

6.  Long-term outcomes of patients with multivessel coronary artery disease presenting non-ST-segment elevation acute coronary syndromes.

Authors:  Piotr Desperak; Michał Hawranek; Paweł Gąsior; Aneta Desperak; Andrzej Lekston; Mariusz Gąsior
Journal:  Cardiol J       Date:  2017-10-05       Impact factor: 2.737

Review 7.  How to treat patients with ST-elevation acute myocardial infarction and multi-vessel disease?

Authors:  Petr Widimsky; David R Holmes
Journal:  Eur Heart J       Date:  2010-11-30       Impact factor: 29.983

Review 8.  Management of Multivessel Coronary Disease in ST-segment Elevation Myocardial Infarction.

Authors:  Amerjeet S Banning; Anthony H Gershlick
Journal:  Curr Cardiol Rep       Date:  2015-09       Impact factor: 2.931

9.  Immediate multivessel revascularization may increase cardiac death and myocardial infarction in patients with ST-elevation myocardial infarction and multivessel coronary artery disease: data analysis from real world practice.

Authors:  Woo-Young Chung; Jae-Bin Seo; Dong-Hyun Choi; Young-Seok Cho; Joo Myung Lee; Jung-Won Suh; Tae-Jin Youn; In-Ho Chae; Dong-Ju Choi
Journal:  Korean J Intern Med       Date:  2016-04-06       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.